Expertise in
10
conditions

Dr. Kanwal P. Raghav

Oncology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Offers Telehealth
Expertise in
10
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Kanwal Raghav is an Oncologist practicing medicine in Cary, North Carolina.

Dr. Raghav is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Appendix Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Hepato-Pancreato-Biliary Surgery, and Splenectomy.

He is actively involved in clinical research, co-authoring 176 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Ceralasertib, Trastuzumab Deruxtecan
Study Phase: Phase 1
A Randomized Study Evaluating Tailoring of Advanced/Metastatic Colorectal Cancer (CRC) Therapy Using Circulating Cell-Free Tumor DNA (ctDNA) (TACT-D)
A Randomized Study Evaluating Tailoring of Advanced/Metastatic Colorectal Cancer (CRC) Therapy Using Circulating Cell-Free Tumor DNA (ctDNA) (TACT-D)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Other, Drug
Study Drugs: Regorafenib, Trifluridine+Tipiracil Hydrochloride
Study Phase: Phase 2
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Cancer of Unknown Primary (SiARa-CUP)
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Cancer of Unknown Primary (SiARa-CUP)
Enrollment Status: Completed
Publish Date: February 25, 2026
Intervention Type: Drug
Study Phase: Phase 2
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors
A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

176 Total Publications

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.
Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.
Journal: Journal for immunotherapy of cancer
Published: August 10, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist practicing medicine in Cary, North Carolina. Dr. Conley is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Alessandra Ferrajoli is an Oncologist practicing medicine in Cary, North Carolina. Dr. Ferrajoli is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Christopher Flowers is an Oncologist practicing medicine in Cary, North Carolina. Dr. Flowers is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Kanwal P. Raghav

How do I make an appointment with Dr. Kanwal P. Raghav?

You can book an appointment with Dr. Kanwal P. Raghav by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kanwal P. Raghav a top-rated expert for Appendix Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kanwal P. Raghav is classified as an Elite expert for Appendix Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kanwal P. Raghav specialize in?

While Dr. Kanwal P. Raghav is a Oncology, they have specific expertise in Appendix Cancer, Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kanwal P. Raghav participate in research or clinical trials?

Yes. Dr. Kanwal P. Raghav has published 176 articles and abstracts on conditions like Appendix Cancer. You can view a list of Dr. Kanwal P. Raghav's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kanwal P. Raghav accept my insurance?

Dr. Kanwal P. Raghav accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raghav's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile